Specification: USP / domestic registration standard
Registration status:
CDE Y20190021168 Status: A
Uses: antitumor drugs.
Properties
Summary
This product is in the form of Mitoxantrone Hydrochloride. Mitoxantrone is a new anti-tumor drug of anthraquinone. Its structure and anti-cancer effect are similar to that of doxorubicin. Because it has no amino sugar structure, does not produce free radicals, and has the effect of inhibiting lipid peroxidation, it has low cardiotoxicity. The mechanism of action shows that Ma can be regarded as a cell cycle nonspecific drug, because it can kill cancer cells in any cell cycle, and the proliferation and non proliferation of cells are inhibited. Mitotic cells were more sensitive than resting cells, and S-phase was the most sensitive.